Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation

New England Journal of Medicine

Volumn 343, Issue 11, 2000, Pages 750-758

  Childs, Richard ^a,b   Chernoff, Allen ^b   Contentin, Nathalie ^a   Bahceci, Erkut ^a   Schrump, David ^c   Leitman, Susan ^d   Read, Elizabeth J ^d   Tisdale, John ^e   Dunbar, Cynthia ^a   Linehan, W Marston ^b   Young, Neal S ^a   Barrett, A John ^a   Clave, Emmanuel ^a   Epperson, Diane ^a   Mayo, Virginia ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE;

ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; KIDNEY CARCINOMA; MALE; METASTASIS; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REMISSION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, RENAL CELL; CYTOKINES; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; KIDNEY NEOPLASMS; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PILOT PROJECTS; PROBABILITY; SURVIVAL ANALYSIS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 0034648702     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200009143431101     Document Type: Article

References (29)

1. Renal-cell carcinoma
2. Systemic therapy for renal cell carcinoma
3. Chemotherapy of renal cell carcinoma: 1983-1989
4. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2
5. Renal cell carcinoma: Antitumor effects of leukocyte interferon
6. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma
7. A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription
8. Molecular expression of PSMA mRNA and protein in primary renal tumors
9. Spontaneous regression of metastases of renal cancer: A report of two cases including the first recorded regression following irradiation of a dominant metastasis and review of the world literature
10. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CDS(+) selected tumor infiltrating lymphocytes from primary tumor
11. Antileukemic effects of graft-versus-host disease in human recipients of allogeneic-marrow grafts
12. Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man
13. Donor leukocyte transfusions for treatment of recurrent chronic myclogenous leukemia in marrow transplant patients
14. Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft-versus-lymphoma effect
15. Graft-versus-myeloma effect in two cases
16. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer
17. Evidence of a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer
18. Engraftment of allogeneic hemato-poietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
19. Nonmyeloablative stem-cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
20. Engraftment kinetics after non-myeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses
21. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation
22. Molecular remission of chronic myeloid leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant: In vivo and in vitro evidence for a graft-versus-leukaemia effect
23. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as a treatment for lymphoid malignancies
24. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: Evidence for a graft-versus-tumor effect
25. Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: Evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA
26. IBMTR Severity Index for grading acute graft-versus-host disease: Retrospective comparison with Glucksberg grade
27. Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: An Illinois Cancer Council Study
28. Twelve-year experience with chemotherapy in adult metastatic renal cell carcinoma at the Institut Gustav-Roussy
29. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia